These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12604537)

  • 1. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
    Zhao X; Eisner W; Perl-Rosenthal N; Kreiswirth B; Drlica K
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1023-7. PubMed ID: 12604537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
    Ince D; Zhang X; Silver LC; Hooper DC
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3370-80. PubMed ID: 12384338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
    Low DE; Muller M; Duncan CL; Willey BM; de Azavedo JC; McGeer A; Kreiswirth BN; Pong-Porter S; Bast DJ
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1119-21. PubMed ID: 11897603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilities.
    Pérez-Vázquez M; Román F; Aracil B; Cantón R; Campos J
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3539-41. PubMed ID: 14576114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
    Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staphylococcus aureus mutants selected by BMS-284756.
    Discotto LF; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3273-5. PubMed ID: 11600399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.
    Bhagwat SS; Mundkur LA; Gupte SV; Patel MV; Khorakiwala HF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3568-79. PubMed ID: 16940059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.
    Morosini MI; Loza E; del Campo R; Almaraz F; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2692-5. PubMed ID: 12878544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.
    Maple PA; Hamilton-Miller JM; Brumfitt W
    Antimicrob Agents Chemother; 1991 Feb; 35(2):345-50. PubMed ID: 1827242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.
    Li Z; Liu Y; Wang R; Li A
    World J Microbiol Biotechnol; 2014 Nov; 30(11):2927-32. PubMed ID: 25129332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.